Oxurion

Oxurion EBIT per Employee

The EBIT per Employee of Oxurion (OXUR.BR) as of Oct 16, 2026 is 4,961.04 EUR. In the previous year, EBIT per Employee was -155,610.39 EUR — a change of -103.19% (higher).

EBIT per Employee

4,961.04EUR

YoY

-103.19%

Last updated:

EBIT per Employee of Oxurion is 2024 4,961.04 EUR. EBIT per Employee of Oxurion was 2023 -155,610.39 EUR. It decreases by -103.19% higher compared to the previous year.

The Oxurion EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2017
302,155.84 EUR
Jan 1, 2018
-509,623.38 EUR
Jan 1, 2019
-458,220.78 EUR
Jan 1, 2020
-370,064.94 EUR
Jan 1, 2021
-355,428.57 EUR
Jan 1, 2022
-285,012.99 EUR
Jan 1, 2023
-155,610.39 EUR
Jan 1, 2024
4,961.04 EUR
The Oxurion EBIT per Employee history
YEAREBIT per EmployeeYoY
4,961.04EUR-103.19%
-155,610.39EUR-45.40%
-285,012.99EUR-19.81%
-355,428.57EUR-3.96%
-370,064.94EUR-19.24%
-458,220.78EUR-10.09%
-509,623.38EUR-268.66%
302,155.84EUR-167.93%
-444,779.22EUR-12.00%
-505,415.58EUR-26.15%
-684,415.58EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

EBIT per Employee of Oxurion is 4,961.04 EUR in 2024.

EBIT per Employee of Oxurion changed from -155,610.39 EUR to 4,961.04 EUR, representing a -103.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Oxurion since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Oxurion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Oxurion

All Key Metrics — Oxurion